Car T Kymriah denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for car t kymriah are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applies Quantity Limits to Kymriah

Kymriah (tisagenlecleucel) is a one-time, patient-specific cell therapy manufactured from the individual patient's own T cells. Quantity-limit denials for Kymriah typically arise in one of two scenarios: (1) the claim coding was structured in a way that triggered an automated quantity-limit edit designed for conventional repeat-dosing drugs, or (2) the insurer is applying a policy that permits only a single infusion and the claim reflects additional supportive or re-infusion services. Understanding which scenario applies determines your appeal strategy.

## Why This Denial Is Appealable

Because Kymriah is administered as a single individualized infusion under its FDA-approved labeling, a quantity-limit denial that would prevent or claw back that single infusion is inconsistent with FDA-approved use. If the denial arose from a coding mismatch, correction of the claim may resolve it without a full appeal. If it reflects a genuine policy dispute, the appeal should center on the prescribing label's dosing structure and the clinical necessity documentation.

## Federal Appeal Framework

• Internal appeal: File within the Explanation of Benefits deadline. Include a cover letter clarifying the nature of Kymriah as a one-time therapy and the clinical basis for the services billed.
• Expedited review: Request if resolution of the dispute would affect the patient's ability to receive or complete treatment.
• External Independent Review (ACA §2719): Available after internal exhaustion; binding on the plan.
• ERISA §503: Full-and-fair review applies to employer plans, with an approximately four-month external-review window from denial.

## Documentation to Gather

1. FDA prescribing label dosing section — obtain the current prescribing information and highlight the dosing structure that defines a single infusion as the standard course. 2. Claim and remittance detail — review exactly which service lines were denied and what quantity limit was applied. 3. Infusion and manufacturing records — documentation from the treatment center confirming what was administered and when. 4. Prescriber letter — a letter confirming the number of infusions administered was consistent with the FDA-approved use and medical necessity. 5. Facility records — any supportive-care services that were billed alongside the infusion, with clinical justification.

## Criteria-Mapping Structure

Obtain UHC's quantity-limit policy for CAR-T therapies and compare it side-by-side with the FDA prescribing label's dosing language. In your appeal table, left column: each quantity-limit criterion or restriction; right column: the label citation, infusion record, or clinical note that shows the administered course was appropriate and within the FDA-approved framework. If the denial was a coding error, include a corrected claim or billing narrative as an exhibit.